JP2014523884A - 細胞外標的化薬物複合体 - Google Patents

細胞外標的化薬物複合体 Download PDF

Info

Publication number
JP2014523884A
JP2014523884A JP2014517251A JP2014517251A JP2014523884A JP 2014523884 A JP2014523884 A JP 2014523884A JP 2014517251 A JP2014517251 A JP 2014517251A JP 2014517251 A JP2014517251 A JP 2014517251A JP 2014523884 A JP2014523884 A JP 2014523884A
Authority
JP
Japan
Prior art keywords
edc
antibody
targeting moiety
linker
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014517251A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523884A5 (cg-RX-API-DMAC7.html
Inventor
ジェイムズ アール． プルデント，
Original Assignee
セントローズ， エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セントローズ， エルエルシー filed Critical セントローズ， エルエルシー
Publication of JP2014523884A publication Critical patent/JP2014523884A/ja
Publication of JP2014523884A5 publication Critical patent/JP2014523884A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Emergency Medicine (AREA)
JP2014517251A 2011-06-24 2012-06-25 細胞外標的化薬物複合体 Pending JP2014523884A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161500756P 2011-06-24 2011-06-24
US61/500,756 2011-06-24
US201161507882P 2011-07-14 2011-07-14
US61/507,882 2011-07-14
US201161551287P 2011-10-25 2011-10-25
US61/551,287 2011-10-25
PCT/US2012/044029 WO2012178173A1 (en) 2011-06-24 2012-06-25 Extracellular targeted drug conjugates

Publications (2)

Publication Number Publication Date
JP2014523884A true JP2014523884A (ja) 2014-09-18
JP2014523884A5 JP2014523884A5 (cg-RX-API-DMAC7.html) 2015-08-13

Family

ID=47423002

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517251A Pending JP2014523884A (ja) 2011-06-24 2012-06-25 細胞外標的化薬物複合体

Country Status (5)

Country Link
US (1) US20140193436A1 (cg-RX-API-DMAC7.html)
EP (1) EP2723393A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014523884A (cg-RX-API-DMAC7.html)
CN (2) CN103732259A (cg-RX-API-DMAC7.html)
WO (1) WO2012178173A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017142083A1 (ja) * 2016-02-18 2018-12-13 国立大学法人京都大学 エクソソームの遺伝子機能を抑制することができる複合体、がんの増殖及び／又は転移抑制剤
JP2022531809A (ja) * 2019-05-14 2022-07-11 デューク ユニバーシティ ＡＴＰａｓｅ媒介性疾患の処置のための組成物および方法
JP2024529067A (ja) * 2021-08-05 2024-08-01 セーンジーン バイオ ユーエスエー インコーポレイティド １’－アルキル修飾リボース誘導体及び使用方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826735C (en) 2003-04-30 2019-06-04 University Of Zurich Methods for treating cancer using an immunotoxin
PL3052525T3 (pl) 2013-10-02 2020-03-31 Viventia Bio Inc. Przeciwciała anty- EpCAM i sposoby wykorzystania
PL3553087T3 (pl) * 2014-01-08 2025-04-28 The Board Of Trustees Of The Leland Stanford Junior University Terapia celowana nowotworu złośliwego płuc
US10675352B2 (en) 2014-02-14 2020-06-09 Centrose, Llc Extracellular targeted drug conjugates
JP2017114763A (ja) * 2014-03-26 2017-06-29 第一三共株式会社 抗ｃｄ９８抗体−薬物コンジュゲート
CA2979394A1 (en) * 2015-03-12 2016-09-15 Viventia Bio Inc. Methods of treatment for epcam positive bladder cancer
JP6847846B2 (ja) 2015-03-12 2021-03-24 セセン バイオ，インコーポレイテッド Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略
EP3328393B1 (en) 2015-07-31 2023-12-20 Centrose, Llc Extracellular drug conjugates targeting cd20
KR101923624B1 (ko) * 2016-07-28 2018-11-30 고려대학교 산학협력단 암세포 화학요법을 위한 agtr1 압타머-항암약물 복합체
AU2019205489A1 (en) * 2018-01-05 2020-06-25 Amgen, Inc. Anti-MCT1 antibodies and uses thereof
MX2020009044A (es) * 2018-03-02 2020-10-12 Evonik Operations Gmbh Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales.
WO2019183375A1 (en) * 2018-03-22 2019-09-26 Eureka Therapeutics, Inc. Antibody agents specifically recognizing monocarboxylate transporter 4 and uses thereof
CA3094311A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
WO2019195423A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
MX2021001281A (es) 2018-08-02 2021-07-15 Dyne Therapeutics Inc Complejos dirigidos a músculos y sus usos para el tratamiento de distrofinopatías.
CA3108335A1 (en) * 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle-targeting complexes and uses thereof
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EA202190416A1 (ru) 2018-08-02 2021-06-23 Дайн Терапьютикс, Инк. Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии
JP7671988B2 (ja) * 2018-12-20 2025-05-07 ウニヴェルズィテート バーゼル 転移の予防又は治療において使用するためのＮａ＋／Ｋ＋ＡＴＰアーゼ阻害剤
US20220243210A1 (en) * 2019-05-17 2022-08-04 Ionis Pharmaceuticals, Inc. Angiotensin ii type 1 receptor targeted oligonucleotides and uses thereof
US20230392163A1 (en) 2019-10-17 2023-12-07 Ginkgo Bioworks Inc. Adeno-associated viral vectors for treatment of niemann-pick disease type c
KR20230068444A (ko) 2020-08-19 2023-05-17 사렙타 쎄러퓨틱스 인코퍼레이티드 레트 증후군의 치료를 위한 아데노 관련 바이러스 벡터
WO2022171195A1 (zh) * 2021-02-11 2022-08-18 兰州大学第二医院 抗cd87抗体与抗pd1抗体联合治疗胃癌
WO2022178754A1 (en) * 2021-02-25 2022-09-01 Shanghai Allygen Biologics Co., Ltd. Targeting conjugates with therapeutic agents and oligonucleotides and uses thereof
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11648318B2 (en) 2021-07-09 2023-05-16 Dyne Therapeutics, Inc. Anti-transferrin receptor (TFR) antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
TWI842088B (zh) 2021-09-14 2024-05-11 美商伊穆諾米塔博立森發展公司 人類單羧酸鹽轉運蛋白1抗體及其用途
EP4508090A1 (en) 2022-04-15 2025-02-19 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy
CN117430697A (zh) * 2022-07-21 2024-01-23 佰舟生物科技(苏州)有限公司 抗mct1抗体及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031870A1 (en) * 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082079A1 (en) * 2001-02-05 2004-04-29 Ralf Besenbruch Low affinity screening method
CN1993146A (zh) * 2004-06-01 2007-07-04 健泰科生物技术公司 抗体－药物偶联物和方法
JP2009529522A (ja) * 2006-03-10 2009-08-20 ディアト 酵素で切断可能なリンカーを介して抗体に複合された抗癌剤
WO2009026274A1 (en) * 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US8007808B2 (en) * 2008-04-04 2011-08-30 The Board Of Trustees Of The Univeristy Of Illinois Composition and method for facilitating the internalization of a therapeutic agent into a cell
EP2334330A4 (en) * 2008-09-29 2013-05-15 Janssen Biotech Inc ANTI-CD147 ANTIBODIES, METHODS, AND USES
US20110070230A1 (en) * 2009-09-24 2011-03-24 Xbiotech, Inc. Method and devices for identifying and treating a subject who has developed an anti-antibody response
CN102933231B (zh) * 2010-02-10 2015-07-29 伊缪诺金公司 Cd20抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031870A1 (en) * 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6016016491; Ｐａｔｈｏｌｏｇｙ　Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｖｏｌ．５６，Ｎｏ．７, 2006, ｐ３５９-３６７ *
JPN6016016493; Ｊｏｕｒｎａｌ　ｏｆ　Ｎｅｕｒｏｓｃｉｅｎｃｅ Ｖｏｌ．２７，Ｎｏ．４５, 2007, ｐ１２３３１-１２３４０ *
JPN6016016495; Ｊｏｕｒｎａｌ　ｏｆ　Ｎｅｕｒｏｃｈｅｍｉｓｔｒｙ Ｖｏｌ．８４，Ｎｏ．３, 2003, ｐ５５７-５６５ *
JPN6016016498; Ｃａｎｃｅｒ　Ｓｃｉｅｎｃｅ Ｖｏｌ．１０１，Ｎｏ．６, 2010, ｐ１４６３-１４７０ *
JPN6016016499; Ｉｎｔｅｒｎａｔｉｏｎａｌ　Ｊｏｕｒｎａｌ　ｏｆ　Ｏｎｃｏｌｏｇｙ Ｖｏｌ．３６，Ｎｏ．１, 2010, ｐ７７-８３ *
JPN6016016502; Ｂｒｉｔｉｓｈ　Ｊｏｕｒｎａｌ　ｏｆ　Ｃａｎｃｅｒ Ｖｏｌ．１０３，Ｎｏ．７, 2010, ｐ１００８-１０１８ *
JPN6016016504; Ｃａｎｃｅｒ　Ｂｉｏｌｏｇｙ　ａｎｄ　Ｔｈｅｒａｐｙ Ｖｏｌ．６，Ｎｏ．６, 2007, ｐ９４２-９４７ *
JPN6016016507; Ｉｍｍｕｎｏｌｏｇｉｃ　Ｒｅｓｅａｒｃｈ Ｖｏｌ．２５，Ｎｏ．１, 2002, ｐ７５-９５ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2017142083A1 (ja) * 2016-02-18 2018-12-13 国立大学法人京都大学 エクソソームの遺伝子機能を抑制することができる複合体、がんの増殖及び／又は転移抑制剤
JP7193083B2 (ja) 2016-02-18 2022-12-20 国立大学法人京都大学 エクソソームの遺伝子機能を抑制することができる複合体、がんの増殖及び／又は転移抑制剤
JP2022531809A (ja) * 2019-05-14 2022-07-11 デューク ユニバーシティ ＡＴＰａｓｅ媒介性疾患の処置のための組成物および方法
JP2024529067A (ja) * 2021-08-05 2024-08-01 セーンジーン バイオ ユーエスエー インコーポレイティド １’－アルキル修飾リボース誘導体及び使用方法

Also Published As

Publication number Publication date
WO2012178173A1 (en) 2012-12-27
CN107080847A (zh) 2017-08-22
EP2723393A1 (en) 2014-04-30
CN103732259A (zh) 2014-04-16
US20140193436A1 (en) 2014-07-10
EP2723393A4 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
JP2014523884A (ja) 細胞外標的化薬物複合体
JP6158962B2 (ja) 細胞外標的化薬物複合体
US20220065862A1 (en) Method for early detection of cancer
JP7038717B2 (ja) アマニチン抗体コンジュゲート
ES2778823T3 (es) Anticuerpos anti-CEACAM5 y usos de los mismos
KR20150119164A (ko) Dll3 결합 시약을 포함하는 암에 대한 치료적 및 진단적 타겟
US20200384122A1 (en) Extracellular targeted drug conjugates
RS58928B1 (sr) Transporter za krvno-moždanu barijeru
AU2017436815B2 (en) Anti-glyco-muc1 antibodies and their uses
US11826399B2 (en) Chlorotoxin agents and uses thereof
Tati et al. Humanization of JAA-F11, a highly specific anti-thomsen-friedenreich pancarcinoma antibody and in vitro efficacy analysis
US20170049908A1 (en) Extracellular targeted drug conjugates
US20250186603A1 (en) Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
JP2004524269A (ja) ノッチレセプターアゴニスト及び用途
JP2022552349A (ja) Ｂリンパ球特異的アマトキシン抗体コンジュゲート
KR20240149030A (ko) 항-bcam 항체 및 항체-약물 접합체

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170302